Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma

NCT04089904 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Low accrual.

Conditions

Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Esophageal Adenocarcinoma

Interventions

DRUG: Pembrolizumab Injection

Sponsor

University of Chicago